S-1: AIxCrypto Holdings Registers $42.5M Stock Resale Amid Pivot to Crypto

AIxCrypto Holdings, Inc. files S-1 for the resale of 18.1 million common shares by selling stockholders, signaling a strategic shift to cryptocurrency treasury operations and addressing Nasdaq compliance.

Summary

• AIxCrypto Holdings, Inc. (formerly Qualigen Therapeutics, Inc.) filed an S-1 registration statement for the resale of up to 18,121,496 shares of common stock by selling stockholders.
• The company will not receive any proceeds from the sale of these shares by the selling stockholders.
• The filing highlights a significant strategic pivot from an early-clinical-stage therapeutics company to one focused on cryptocurrency treasury operations, initiated on October 12, 2025.
• The cryptocurrency treasury employs an 80% passive allocation (tracking the C10 index) and a 20% active allocation (quant analysis, hedging strategies).
• A private placement offering closed on September 29, 2025, raising $41,000,000 in cash from investors, including Faraday Future Intelligent Electric Inc. as the Lead Investor.
• Proceeds from the private placement are allocated: up to $6,800,000 for existing debt and business operations, with the balance for establishing cryptocurrency treasury operations.
• The company obtained stockholder approval on November 12, 2025, for the conversion of Series B Preferred Stock, which was a condition for exceeding Nasdaq's 19.99% issuance cap.
• The company regained compliance with Nasdaq's timely SEC reporting rule and satisfied the $2.5 million stockholders' equity requirement prior to the September 30, 2025 deadline, primarily due to the private placement proceeds.
• The company's common stock trades on The Nasdaq Capital Market under the symbol AIXC, with a last reported sales price of $2.35 per share on December 1, 2025.
• A 1-for-50 reverse stock split was implemented on November 5, 2024.
• The company continues to advance its QN-302 therapeutic program, which is in a Phase 1a clinical trial for pancreatic cancer and has Orphan Drug Designation.
• The Pan-RAS preclinical program's out-license agreement with Pan-RAS Holdings was terminated on March 16, 2024.
• The company has increased its secured demand promissory note with Marizyme, Inc. to approximately $4.77 million as of October 30, 2025, bearing 18% interest and maturing on August 21, 2026.

Sentiment

Score: 6

Explanation: The filing presents a mixed bag. The successful $41M capital raise and resolution of Nasdaq compliance issues are significant positives, indicating a stronger financial position and continued listing. The strategic pivot to crypto is a bold move with potential upside. However, the company still faces substantial doubt about its ability to continue as a going concern, has recurring losses, an accumulated deficit, and identified material weaknesses in internal controls. The Marizyme debt is also a concern. The shift to crypto introduces new, high-volatility risks. The overall sentiment is cautiously optimistic due to the capital infusion and strategic shift, but tempered by underlying financial instability and new market risks.

Positives

• Successfully closed a $41,000,000 private placement offering on September 29, 2025, providing significant capital.
• Proceeds from the private placement allowed the company to satisfy Nasdaq's $2.5 million stockholders' equity requirement prior to the September 30, 2025 deadline, resolving a critical compliance issue.
• Regained compliance with Nasdaq Listing Rule 5250(c)(1) regarding timely SEC reporting.
• Strategic pivot to cryptocurrency treasury operations, diversifying the business model into a high-growth sector.
• QN-302 program for pancreatic cancer has Orphan Drug Designation from the FDA, offering potential seven-year marketing exclusivity and federal tax credits.
• First patient dosed in Phase 1a clinical trial for QN-302, indicating progress in drug development.
• Appointment of Jiawei Wang as Co-Chief Executive Officer and Koti Meka as Chief Financial Officer, strengthening the management team for the new strategic direction.

Negatives

• The company will not receive any proceeds from the current resale of 18,121,496 shares by selling stockholders.
• The company has a working capital deficiency, a stockholders' equity deficit, and recurring losses from operations, which raise substantial doubt about its ability to continue as a going concern.
• Identified material weaknesses in internal control over financial reporting, including a lack of accounting resources and inadequate segregation of duties.
• The out-license agreement for the Pan-RAS drug development program with Pan-RAS Holdings was terminated on March 16, 2024, indicating a setback for that program.
• The company requires additional cash resources to continue and complete the Phase 1a clinical trial for QN-302.
• The Marizyme demand promissory note has increased to approximately $4.77 million as of October 30, 2025, bearing 18% interest, and there is no assurance Marizyme will repay it.

Risks

• Sales of a substantial number of shares by the Selling Stockholders may cause the price of common stock to decline.
• The issuance of common stock upon conversion of the Series B Preferred will cause substantial dilution to existing stockholders.
• Failure to maintain compliance with Nasdaq continued listing requirements could lead to delisting.
• Common stock has experienced and may continue to experience significant price and volume volatility.
• Future equity financings may further dilute stockholders or adversely affect the stock price.
• Financial condition raises substantial doubt about the ability to continue as a going concern, with an accumulated deficit of approximately $123.1 million as of December 31, 2024.
• Failure to remediate material weaknesses in internal controls could adversely affect business and stock price.
• No assurance that Marizyme will be able to repay the Amended Note when due, potentially leading to nonpayment or default.
• The value of collateral securing the Marizyme Amended Note may be insufficient to cover the debt.
• Enforcement actions against Marizyme in case of default could be costly, time-consuming, and uncertain.
• Operating results will significantly fluctuate due to the highly volatile nature of the cryptoeconomy and crypto asset prices.
• The future development and growth of crypto is subject to a variety of unpredictable factors, including regulatory changes, security issues, and network vulnerabilities.
• Cyberattacks and security breaches of the platform or third parties could harm brand, reputation, business, operating results, and financial condition.
• Subject to an extensive, highly-evolving, and uncertain regulatory landscape for crypto, with potential for significant fines or limitations for non-compliance.
• Operates in a highly competitive industry, including against unregulated or less regulated companies with greater resources.
• May become subject to litigation, investigations, and enforcement actions by regulators and governmental authorities, which are expensive and time-consuming.
• Uncertainty regarding the status of crypto assets, products, or services as securities could lead to regulatory scrutiny and penalties.
• Reliance on third-party service providers for operations, with potential for interruptions or failures.
• Strategy focused on long-term compliance and security may not maximize short-term or medium-term financial results.
• Acquisitions and investments could require significant management attention, disrupt business, result in dilution, and adversely affect business, operating results, and financial condition.
• Due to unfamiliarity and negative publicity associated with crypto asset platforms, confidence or interest in crypto asset platforms may decline.
• Future developments regarding the treatment of crypto assets for U.S. and foreign tax purposes could adversely affect the business.
• Additional risks and uncertainties not currently known or deemed immaterial may also materially and adversely affect the business.

Future Outlook

The company intends to continue its strategic pivot into cryptocurrency treasury operations, utilizing an 80% passive and 20% active allocation strategy, with plans to upgrade the active allocation to include hedging strategies. It also aims to continue the Phase 1a clinical trial for QN-302, which will require additional funding. The company will need to successfully remediate internal control weaknesses and maintain Nasdaq listing compliance. Management is exploring further financing, strategic, and operational opportunities.

Management Comments

• "We are utilizing an 80% passive and 20% active allocation strategy with 80% of the C10 Treasury closely tracking the C10 index, investing in the top 10 cryptocurrencies based on market capitalization, and 20% of the Treasury being allocated to the top 10 cryptocurrencies based on the teams quantitative analysis."
• "The 20% active allocation strategy will be further upgraded to include active hedging strategies including stablecoins, options, and structured products."
• "We intend to employ, among other things, a Quantitatively Driven module to help accurately identify those fundamentally superior assets that have been mis-prioritized in the cryptocurrency market."
• "We believe that QN-302 has the potential to demonstrate superior efficacy and activity against pancreatic ductal adenocarcinoma (PDAC)."
• "Management is exploring financing, strategic, and operational opportunities; however, there can be no assurance that these efforts will be successful."

Industry Context

This filing reflects a significant trend of companies diversifying into the cryptocurrency space, often driven by the potential for high growth and new revenue streams, while also navigating the complex and evolving regulatory landscape of digital assets. The company's dual focus on early-stage biotech and crypto treasury operations positions it uniquely, but also exposes it to the distinct risks and competitive pressures of both highly speculative sectors. The move into crypto is a clear attempt to capitalize on market interest and potentially improve financial standing, especially given the "going concern" qualification. The biotech segment, with its focus on oncology, operates within a highly regulated and capital-intensive industry characterized by long development cycles and high failure rates.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• Acquired 52.8% interest in NanoSynex from Alpha Capital Anstalt (Alpha), a related party, on May 26, 2022.
• Issued 7,000 shares of common stock and a pre-funded common stock purchase warrant to Alpha in exchange for NanoSynex preferred shares on May 26, 2022.
• Issued Alpha an 8% Senior Convertible Debenture for $3,300,000 (purchase price $3,000,000) on December 22, 2022, and a warrant to purchase 50,000 shares.
• Issued common stock to Alpha in lieu of cash for monthly redemption payments on the 2022 Debenture in October and December 2023, and February, March, April, and May 2024.
• Issued Alpha an 8% Convertible Debenture for $550,000 (purchase price $500,000) on February 27, 2024, and a warrant to purchase 18,000 shares.
• Alpha assigned a purchase option right to Yi Hua Chen, who then received an 8% Convertible Debenture for $1,100,000 (purchase price $1,000,000) and a warrant to purchase 36,001 shares on April 12, 2024.
• Faraday Future Intelligent Electric Inc. (Lead Investor) is a selling stockholder and has significant influence through the Lead Investor Agreement, including board appointments and treasury policy. Jiawei Wang, Co-CEO of AIxCrypto, is also President of Faraday Future Intelligent Electric, Inc. Yueting Jia, a selling stockholder, has voting and investment control of shares held by Faraday Future Intelligent Electric Inc.

Stakeholder Impact

• Shareholders: Potential for significant dilution from the conversion of Series B Preferred Stock and future equity financings. The stock price may be volatile due to the resale of shares and the highly speculative nature of crypto assets. The strategic pivot introduces new investment risks and opportunities.
• Employees: Management changes (new Co-CEO, CFO, board resignations/appointments) may impact corporate culture and strategic direction.
• Customers (of DuraGraft): Continued financial support for Marizyme's DuraGraft solution could lead to its commercialization, benefiting patients undergoing coronary artery bypass grafting surgeries.
• Creditors: The company's "going concern" qualification and recurring losses indicate elevated risk for creditors, though the recent capital raise provides some relief. The Marizyme note is secured, but recovery is not assured.
• Regulatory Bodies: The company's shift into crypto assets will likely increase scrutiny from regulatory bodies regarding compliance with evolving laws and regulations in the cryptoeconomy.

Next Steps

• Continue and complete the Phase 1a clinical trial for QN-302, requiring additional cash resources.
• Further upgrade the 20% active cryptocurrency allocation strategy to include active hedging strategies (stablecoins, options, structured products).
• Employ a Quantitatively Driven module to identify fundamentally superior crypto assets.
• Remediate material weaknesses in internal controls over financial reporting.
• File a registration statement for the resale of the common stock and conversion shares from the private placement within 45 days of the September 29, 2025 closing.
• Maintain the effectiveness of the resale registration statement.
• Explore financing, strategic, and operational opportunities to address going concern issues.

Key Dates

Recommendation

The company has undergone a significant transformation, raising substantial capital and pivoting to a new, high-growth, but also high-risk, industry (cryptocurrency). While the capital raise and Nasdaq compliance resolution are positive, the underlying "going concern" issues, recurring losses, and material weaknesses in internal controls remain. The dual focus on early-stage biotech and crypto treasury operations creates a complex risk profile. The current filing is primarily for the resale of shares by existing stockholders, meaning no direct capital infusion from this specific offering. Given the recent strategic shift and the inherent volatility and regulatory uncertainty in the crypto space, coupled with ongoing challenges in the biotech segment, a "hold" recommendation is appropriate. Investors should monitor the execution of the crypto strategy, progress in the QN-302 clinical trial, and the remediation of internal control weaknesses before considering further investment. The stock is highly speculative.

Keywords

cryptocurrency, biotechnology, SEC filing, S-1, AIxCrypto Holdings, AIXC, Nasdaq, stock resale, private placement, Series B Preferred Stock, QN-302, pancreatic cancer, Orphan Drug Designation, Pan-RAS, Marizyme, DuraGraft, going concern, internal controls, stock dilution, crypto treasury, financial reporting, corporate governance, risk management